Your AI-Trained Oncology Knowledge Connection!

Martin Dreyling, MD

home / authors / martin-dreyling-md

Articles

MCL Treatment Advances and Future Directions

February 12th 2024

Martin Dreyling, MD, spoke about the potential use of CAR T-cell therapy in earlier treatment stages for certain patient groups with mantle cell lymphoma.

The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.

Unraveling Resistance and Heterogeneity in Mantle Cell Lymphoma Management

Elias Campo, MD, PhD;Michael Wang, MD;Martin Dreyling, MD;Julie M. Vose, MD, MBA

February 5th 2024

The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.

$Copanlisib Yields Responses in Relapsed/Refractory Non-Hodgkin Lymphoma$

Copanlisib Yields Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

Martin Dreyling, MD

April 5th 2017

This video reviews results of the phase II CHRONOS-1 trial, a single-arm study evaluating the investigational agent copanlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.